BMS-F is a chemical from the aminoalkylindole family invented by Bristol-Myers Squibb around 1999, that acts as a potent and selective agonist for the cannabinoid receptor CB<sub>2</sub>, with a K<sub>i</sub> of 8 nM at CB<sub>2</sub> and 500x selectivity over the related CB<sub>1</sub> receptor. It has antiinflammatory effects and inhibits release of TNF-ñ.